Abbott denosumab biosimilar has received regulatory approval in Thailand, expanding access to advanced therapies for osteoporosis and cancer-related bone loss. With this introduction, treatment will become more affordable and accessible for the estimated 3 million people suffering from osteoporosis and bone-disease related illness in the country.

"For people living with osteoporosis or cancer-related bone disease, access to a denosumab biologic can be truly life-changing," said Karim Elmashad, divisional vice president of medicines business in Asia Pacific. "With this approval, people in Thailand affected by these conditions now have greater access to this transformative therapy."

Addressing a growing health challenge
Osteoporosis, a chronic and age-related disease, is a serious public health concern. The condition has a significant and often debilitating impact, including fractures that lead to loss of independence and reduced quality of life. In Thailand, 1 in 5 women and 1 in 10 men have osteoporosis, with prevalence increasing significantly with age. As the country's population ages — projected to reach 25% aged 60 or older within the next decade — the burden of osteoporosis-related fractures, disability, and healthcare costs is expected to rise sharply.

Fractures caused by osteoporosis can lead to loss of independence and reduced quality of life. Yet fewer than 40% of hip fracture patients in Thailand begin anti-osteoporosis therapy, often due to barriers such as cost, awareness, and treatment availability.

The denosumab biosimilar will be provided as part of a broader strategy to expand access to high-quality medicines across key therapeutic areas including oncology, immunology, and women's health through strategic partnerships with biotechnology companies.

With a long history of delivering healthcare solutions, the company remains committed to helping people live their best at every stage of life. Building on its well-established biosimilars portfolio in Latin America and India, and following a recent biosimilar launch in Malaysia, the introduction of denosumab in Thailand marks a significant step in addressing the region's growing burden of chronic diseases, while expanding access to a high-quality treatment at a more accessible price.